Back to Archived News
Nanogen Extends IP Portfolio with Nucleic Acid Detection and Genotyping Technology Patents
Monday, October 01, 2007
San Diego, CA -- Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has been granted United States Patent No. 7,252,940, titled "Abasic site endonuclease assay" from the U.S. Patent and Trademark Office. The technology described in the patent extends the underlying proprietary real-time PCR technology used in the Company’s MGB Alert® products to a new product offering that has been commercialized as research reagents for use in replication validation following genome wide scanning in pharmaceutical and biotechnology industry labs. This technology is also ideal for genetic analysis in multiplex formats of complex genetic diseases.
The unique construct of these assay reagents provides researchers with a method for high throughput validation of SNPs (single nucleotide polymorphisms) discovered during genome wide scanning. The goal of many genome wide scanning projects is to identify SNPs associated with particular diseases, such as diabetes or heart failure, in order to identify therapeutic targets or develop diagnostic assays. In order to establish clear disease association, SNPs are validated across large sample populations, often on the order of tens of thousands. This newly patented technology provides the ability to test large numbers of SNPs in parallel across a large number of samples to complete validation in a relatively rapid manner.
Nanogen has also been awarded U.S. Patent No. 7,205,105, "Real-time linear detection probes: sensitive 5’-minor groove binder-containing probes for PCR analysis," related to the probes employed in its MGB Alert® line of reagents. These probes are an important part of the Company’s proprietary product offering designed to assist clinical laboratories in developing molecular diagnostic tests that will detect genetic sequences associated with pathogens including those often tested in immunocompromised patients such as cytomegalovirus, Epstein-Barr virus, and enterovirus.
About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen’s website at www.nanogen.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Back to Archived News
